醫藥股造好 藥明生物 信達、百濟神州及康方漲6%-12%
滬指及深成反覆回升0.2%及0.8%,現報3,394及12,966。醫藥生物板塊急升3.8%。
本港醫藥股也逆市造好,尤其是康方生物(09926.HK)扭兩連跌,午後高見26.6元,現報25.85元,急漲12%。百濟神州(06160.HK)回升8%報106.4元。信達生物(01801.HK)午後高見38.2元,現報37.85元,續升8.6%。
藍籌藥明生物(02269.HK)扭四連跌,午後高見77.45元,現報76.05元,回升5.9%。藥明康德(02359.HK)續升逾5%曾高見112.3元,藥明康德A(603259.SH)升6.5%曾高見109.92元人民幣。
藍籌中生製藥(01177.HK)及石藥(01093.HK)兩連升,報5.27元及8.13元,續升6%及4.4%。金斯瑞生物(01548.HK)續升8.8%報30.95元
君實生物(01877.HK)及威高股份(01066.HK)升逾2%-3%,後者股價兩連升曾高見9.96元,現報9.41元,續升3.2%。
恆指繼今早一度跌1.8%至21,458獲承接後,午後曾倒升高見21,886,現報21,774,僅續跌85點或0.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.